0000902664-23-004381.txt : 20230811 0000902664-23-004381.hdr.sgml : 20230811 20230811161516 ACCESSION NUMBER: 0000902664-23-004381 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALLURION TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001964979 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-94138 FILM NUMBER: 231164291 BUSINESS ADDRESS: STREET 1: 11 HURON DR STE 200 CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-647-4000 MAIL ADDRESS: STREET 1: 11 HURON DR STE 200 CITY: NATICK STATE: MA ZIP: 01760 FORMER COMPANY: FORMER CONFORMED NAME: ALLURION TECHNOLOGIES HOLDINGS, INC. DATE OF NAME CHANGE: 20230207 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RTW INVESTMENTS, LP CENTRAL INDEX KEY: 0001493215 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 40 10TH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-597-6980 MAIL ADDRESS: STREET 1: 40 10TH AVENUE STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: RTW INVESTMENTS, LLC DATE OF NAME CHANGE: 20100602 SC 13D 1 p23-2162sc13d.htm ALLURION TECHNOLOGIES INC.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

ALLURION TECHNOLOGIES HOLDINGS, INC.
(Name of Issuer)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

G02008102
(CUSIP Number)

RTW Investments, LP
Attn: Roderick Wong, M.D.
40 10^th Avenue, Floor 7
New York, New York 10014
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 1, 2023
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Page 1 of 13 Pages)

CUSIP No. G02008102

13D

Page 2 of 13 Pages

1	NAME OF REPORTING PERSON RTW Investments, LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 3,457,707
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 3,457,707
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 3,457,707
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.4⁽¹⁾
14	TYPE OF REPORTING PERSON PN, IA

⁽¹⁾ Percentage based upon 46,502,000 shares of the Company’s common stock outstanding as of August 1, 2023, as represented to the Reporting Persons by the Company.

CUSIP No. G02008102

13D

Page 3 of 13 Pages

1	NAME OF REPORTING PERSON Roderick Wong, M.D.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ¨ (b) ¨
3	SEC USE ONLY
4	SOURCE OF FUNDS AF
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)		¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 3,457,707
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 3,457,707
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 3,457,707
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES			¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.4⁽¹⁾
14	TYPE OF REPORTING PERSON IN, HC

⁽¹⁾ Percentage based upon 46,502,000 shares of the Company’s common stock outstanding as of August 1, 2023, as represented to the Reporting Persons by the Company.

CUSIP No. G02008102

13D

Page 4 of 13 Pages

Item 1.	Security and Issuer

This statement on Schedule 13D relates to shares of common stock, par value $0.0001 (the “Shares”), of Allurion Technologies Holdings, Inc., a Delaware corporation (the “Company”), having its principal executive offices at 11 Huron Drive, Natick, MA 01760.

Item 2.	Identity and Background

(a) This statement is filed by (i) RTW Investments, LP, a Delaware limited partnership (“RTW Investments”), and the investment adviser to certain funds (the “RTW Funds”), with respect to the Shares directly held by the RTW Funds; and (ii) Roderick Wong, M.D., a United States citizen (“Dr. Wong”), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. Each of RTW Investments and Dr. Wong (each a “Reporting Person” and together, the “Reporting Persons”) is filing this statement.

(b) The address of the principal business office of RTW Investments and Dr. Wong is 40 10th Avenue, Floor 7, New York, New York 10014.

(c) The principal business of RTW Investments is serving as investment advisor to the RTW Funds. The principal occupation of Dr. Wong is to serve as the Managing Partner and Chief Investment Officer of RTW Investments.

(d) No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) No Reporting Person has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) RTW Investments is a limited partnership organized in Delaware. Dr. Wong is a citizen of the United States of America.

Item 3.	Source and Amount of Funds or Other Consideration.

The source of funds used for the purchase of the Shares reported herein was the working capital of the RTW Funds. The aggregate purchase price of the Shares reported herein was approximately $17.25 million, along with such other consideration as is described in Item 4 below.

CUSIP No. G02008102

13D

Page 5 of 13 Pages

Item 4.	Purpose of Transaction.

*Business Combination Agreement*

On February 9, 2023, Compute Health Acquisition Corp. (“CPUH”) entered into a business combination agreement (the “Business Combination Agreement”) with Compute Health Corp., a Delaware corporation and direct, wholly-owned subsidiary of CPUH (“Merger Sub I”), Compute Health LLC, a Delaware limited liability company and direct, wholly-owned subsidiary of CPUH (“Merger Sub II” and, together with Merger Sub I, the “Merger Subs”), the Company, and Allurion Technologies, Inc., a Delaware corporation (“Allurion” and, collectively with CPUH, the Merger Subs and the Company, the “Parties”).

Pursuant to the Business Combination Agreement, and upon the terms and subject to the conditions set forth therein, the business combination was effected in three steps: (a) CPUH merged with and into the Company (the “CPUH Merger,” the closing of the CPUH Merger, the “CPUH Merger Closing” and the time at which the CPUH Merger became effective, the “CPUH Merger Effective Time”), with the Company surviving (the Company, in its capacity as the surviving company in the CPUH Merger, the “Surviving Corporation”) and, after giving effect to such merger, becoming the publicly-listed company and the sole owner of each Merger Sub, (b) following the consummation of the CPUH Merger, Merger Sub I merged with and into Allurion (the “Intermediate Merger,” the closing of the Intermediate Merger, the “Intermediate Merger Closing” and the time at which the Intermediate Merger became effective, the “Intermediate Merger Effective Time”), with Allurion surviving as the surviving company in the Intermediate Merger (Allurion, in its capacity as the surviving company in the Intermediate Merger, the “Intermediate Surviving Corporation”) and, after giving effect to such merger, becoming a wholly-owned subsidiary of the Surviving Corporation and (c) thereafter, the Intermediate Surviving Corporation merged with and into Merger Sub II (the “Final Merger,” and the time at which the Final Merger became effective, the “Final Merger Effective Time”) (the Final Merger, collectively with the CPUH Merger and the Intermediate Merger, the “Mergers” and, together with the other transactions contemplated by the Business Combination Agreement and the Ancillary Documents (as defined in the Business Combination Agreement), the “Proposed Transactions”), with Merger Sub II surviving as the surviving company in the Final Merger (Merger Sub II, in its capacity as the surviving company of the Final Merger, the “Surviving Subsidiary Company”) and, after giving effect to such merger, remaining a wholly-owned subsidiary of the Surviving Corporation.

Upon the closing of the Mergers on August 1, 2023 (collectively, the “Closing”), the Surviving Corporation changed its name to “Allurion Technologies, Inc.” and commenced trading on the New York Stock Exchange (the “NYSE”) under the ticker symbol “ALUR”.

A copy of the Business Combination Agreement was filed as an exhibit to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023. The foregoing description of the Business Combination Agreement and the Mergers does not purport to be complete and is qualified in its entirety by reference thereto.

CUSIP No. G02008102

13D

Page 6 of 13 Pages

Investor Rights Agreement

In connection with the Closing, the Company, Compute Health Sponsor LLC, a Delaware limited liability company (the “Sponsor”), the RTW Funds and certain other parties entered into an Investor Rights and Lock-up Agreement (the “Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, upon the terms and subject to the conditions set forth therein, each signatory thereto (other than the Company) was granted certain registration rights with respect to their respective Shares.

Additionally, pursuant to the Investor Rights Agreement, upon the terms and subject to the conditions set forth therein, following the Closing, the board of directors of the Surviving Corporation shall consist of seven (7) directors, a majority of which shall be “independent” directors (“Independent Directors”) for purposes of NYSE rules, and the following persons will have the following nominations rights with respect to the Surviving Corporation’s board of directors, subject to the limitations set forth in the Investor Rights Agreement: (i) one (1) director and one (1) Independent Director will be nominated by Shantanu Gaur; (ii) one (1) director and one (1) Independent Director will be nominated by Remus Capital (as defined in the Investor Rights Agreement); (iii) one (1) director will be nominated by the Sponsor; and (iv) two (2) Independent Directors will be nominated by Allurion (one of which shall be designated by RTW (pursuant to the RTW Side Letter (as defined and described below)).

A copy of the Investor Rights Agreement is filed as an exhibit hereto and is incorporated herein by reference. The foregoing description of the Investor Rights Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

PIPE Subscription Agreements

On February 9, 2023, in connection with the execution of the Business Combination Agreement, CPUH and the Company entered into subscription agreements with certain investors (the “Subscription Agreements” and such investors, the “Investors”), pursuant to which, upon the terms and subject to the conditions set forth therein, the Investors, among other things, subscribed to purchase an aggregate of 5,386,695 Shares (collectively, the “Subscriptions”) for a purchase price of $7.04 per share (other than as described in the RTW Side Letter below), for an aggregate purchase price of $37,922,363, which shares were issued immediately prior to the Intermediate Merger Effective Time (the “PIPE Financing”). In connection with the PIPE Financing, RTW subscribed to purchase an aggregate of 2,130,681 Shares for an aggregate purchase price of $14,999,994.24. The obligations of each party to consummate the Subscriptions were conditioned upon, among other things, customary closing conditions and the consummation of the Proposed Transactions.

Copies of the forms of Subscription Agreements are filed as exhibits hereto and are incorporated herein by reference. The foregoing description of the Subscription Agreements and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

CUSIP No. G02008102

13D

Page 7 of 13 Pages

RTW Side Letter

On February 9, 2023, in connection with the execution of the Business Combination Agreement, the Subscription Agreements and the Revenue Interest Financing Agreement (as defined below), CPUH, the Company, Allurion and Merger Sub II entered into a side letter (the “RTW Side Letter”) with RTW Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, RTW Innovation Master Fund, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, and RTW Biotech Opportunities Ltd, an investment company limited by shares incorporated under the laws of Guernsey (formerly known as RTW Venture Fund Limited) (collectively, “RTW”), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, (a) CPUH and the Company agreed not to enter into Subscription Agreements with Investors on more favorable or advantageous terms than those included in the Subscription Agreements to be entered into by and among CPUH, the Company and RTW, (b) the Company agreed to convert up to 50% of the consideration RTW paid to the Company in connection with the PIPE Financing by forfeiting Shares into financing provided by RTW to CPUH pursuant to an Additional Revenue Interest Financing Agreement (as defined in the RTW Side Letter), (c) the Company agreed to issue up to an additional 1,000,000 Shares to RTW (the “Additional RTW Shares”), with (i) 250,000 of such Additional RTW Shares to be issued at the Closing and not subject to any contingencies and (ii) 750,000 of such Additional RTW Shares to be issued based on the minimum cash of CPUH as of immediately prior to the Intermediate Merger Effective Time (to be determined linearly, based on no Additional RTW Shares being issuable if such minimum cash is equal to or greater than $100 million and 750,000 Additional RTW Shares being issuable if such minimum cash is $70 million), (d) the Company agreed that RTW shall have the right to designate one Independent Director to the Surviving Corporation’s board of directors, who is initially Nicholas Lewin, and (e) the Company agreed to create the board position of lead independent director, who shall serve as chair or co-chair of the Surviving Corporation’s board of directors, and who is initially Omar Ishrak.

On May 2, 2023, pursuant to the Backstop Agreement (as defined below) and contemporaneously with the execution of the Backstop Agreement, CPUH, the Company, Merger Sub II, Allurion and RTW entered into an amended and restated side letter (the “Amended and Restated RTW Side Letter”), which amends and restates the RTW Side Letter in its entirety, in order to reflect that any conditional Additional RTW Shares under the Amended and Restated RTW Side Letter would be calculated net of any Shares issuable to RTW under the Backstop Agreement. Additionally, pursuant to the Amended and Restated RTW Side Letter, the parties to the Amended and Restated RTW Side Letter agreed that, if a third party subsequently provides Allurion with debt financing on more favorable terms than those provided to RTW under the Backstop Agreement, RTW will be offered the same or more favorable terms and conditions as Allurion provided to such third party.

On July 28, 2023, RTW assigned the Amended and Restated RTW Side Letter, in part, to certain entities which have engaged RTW Investments as their investment manager.

CUSIP No. G02008102

13D

Page 8 of 13 Pages

Pursuant to the terms of the Amended and Restated RTW Side Letter, at the Closing, the Company issued 250,000 Additional RTW Shares pursuant to clause (i) above and no contingent Additional RTW Shares pursuant to clause (ii) above.

Copies of the RTW Side Letter and the Amended and Restated RTW Side Letter are filed as exhibits hereto and are incorporated herein by reference. The foregoing description of such agreements and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

Revenue Interest Financing

On February 9, 2023, in connection with the execution of the Business Combination Agreement, Allurion and RTW entered into an agreement, pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, RTW agreed to provide financing to Allurion at the Closing in the initial amount of $40 million in exchange for a revenue interest in Allurion’s current and future products and digital solutions (the “Revenue Interest Financing Agreement” and such financing, the “Revenue Interest Financing”).

On July 28, 2023, RTW assigned the Revenue Interest Financing Agreement to certain entities which have engaged RTW Investments as their investment manager.

A copy of the Revenue Interest Financing Agreement is filed as an exhibit hereto and is incorporated herein by reference. The foregoing description of the Revenue Interest Financing Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

Convertible Note Purchase Agreement

On February 15, 2023, Allurion, Hunter Ventures Limited (“HVL”) and RTW entered into an agreement, pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, RTW agreed to purchase from Allurion Convertible Unsecured Promissory Notes (as defined therein) in an aggregate principal amount equal to $250,000 (the “Convertible Note Purchase Agreement”).

Effective as of the Closing, the Convertible Unsecured Promissory Notes were converted into 43,022 Shares.

A copy of the Convertible Note Purchase Agreement is filed as an exhibit hereto and is incorporated herein by reference. The foregoing description of the Convertible Note Purchase Agreement and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

CUSIP No. G02008102

13D

Page 9 of 13 Pages

Backstop Agreement

On May 2, 2023, CFIP2 ALLE LLC (“Fortress”) and RTW (together, the “Backstop Purchasers”) entered into a Backstop Agreement with Allurion, the Company and HVL (the “Backstop Agreement”). Pursuant to the Backstop Agreement, upon the terms and subject to the conditions set forth therein, each Backstop Purchaser agreed that, to the extent any portion of that certain $13 million Bridge Note sold to HVL on February 15, 2023 (the “HVL Bridge Note”) remained outstanding following the Determination Time (as defined therein), such Backstop Purchaser would, at a closing to take place at the same time, on the same date and concurrently with but immediately prior to the closing of the Intermediate Merger (the “Backstop Closing” and the date on which such closing occurs, the “Backstop Closing Date”), purchase up to $2 million aggregate principal amount (the “Maximum Purchase Amount”) of the HVL Bridge Note from HVL.

In addition, in the event that the Backstop Purchase Amount (as defined in the Backstop Purchase Agreement) for RTW was equal to its Maximum Purchase Amount, the Company agreed to, no later than the Backstop Closing Date, issue to RTW a number of Shares equal to the greater of (i) 700,000 Shares and (ii) the number of Shares issuable to RTW pursuant to the Amended and Restated RTW Side Letter.

On July 24, 2023, certain entities which have engaged RTW Investments as their investment manager joined the Backstop Agreement.

Pursuant to the Backstop Agreement, on August 1, 2023, (i) RTW purchased $2 million aggregate principal amount of the HVL Bridge Note from HVL and (ii) the Company issued 700,000 Shares to certain entities which have engaged RTW Investments as their investment manager.

Effective as of the Closing, RTW’s portion of the HVL Bridge Note was converted into 334,004 Shares.

A copy of the Backstop Agreement is filed as an exhibit hereto and is incorporated herein by reference, and the foregoing description of the Backstop Agreement. The transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference thereto.

Plans or Proposals

Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Persons, at any time and from time to time, may review, reconsider, and change their position and/or change their purpose and/or develop such plans.

CUSIP No. G02008102

13D

Page 10 of 13 Pages

The Reporting Persons, among other things, intend to have discussions with representatives of the Company’s management and board of directors relating to a variety of matters that the Reporting Persons believe will increase shareholder value, including, operational, financial, corporate governance, board composition, management, capitalization, accounting, strategic direction, and Share performance matters. The Reporting Persons have also engaged, and intend to continue to engage, in discussions with other current or prospective shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit, and other third parties regarding a variety of matters relating to the Company and the Shares, including each of the operational, financial, corporate governance, management, capitalization, accounting, strategic direction and share performance matters noted herein. The Reporting Persons may also take other steps seeking to bring about changes to increase shareholder value.

The Reporting Persons may from time to time and at any time: (i) acquire additional Shares and/or other securities and/or instruments (including equity, debt or other securities or instruments) of the Company (or its affiliates) in the open market, in privately negotiated transactions, or otherwise; (ii) dispose of any or all of their Shares and/or other securities and/or instruments of the Company (or its affiliates) in the open market, in privately negotiated transactions, or otherwise; (iii) enter into swap and/or other derivative transactions with broker-dealers and/or financial institutions counterparties with respect to the securities of the Company (or its affiliates) which may be deemed to either increase or decrease the Reporting Persons’ economic exposure to the value of the Shares or other securities of the Company; and/or (iv) engage in any other hedging or similar transactions with respect to the Shares and/or other securities or instruments of the Company.

Item 5.	INTEREST IN SECURITIES OF THE ISSUER

(a)	The aggregate percentage of Shares reported to be beneficially owned by the Reporting Persons is based upon 46,502,000 Shares outstanding as of August 1, 2023, as represented to the Reporting Persons by the Company.
(b)	See rows (7) through (10) of the cover page to this Schedule 13D for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

(c)	Except as otherwise described herein, the Reporting Persons did not effect any transactions with respect to the Shares during the past sixty (60) days.

(d)	No person, other than the Reporting Persons and the RTW Funds, has the right to receive or the power to direct the receipt of dividends or proceeds of sale of the Shares reported herein.

(e)	Not applicable.

CUSIP No. G02008102

13D

Page 11 of 13 Pages

Item 6.	CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
	Except as otherwise described herein, including Item 4 above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Company, including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

	The Reporting Persons may from time to time enter into one or more cash-settled equity swaps with broker-dealers or other financial institutions counterparties with respect to the Shares and/or other securities of the Company, with reference prices and maturity dates that vary depending upon the terms of each such cash-settled swap. After giving effect to such transactions, the Reporting Persons may be deemed to have either increased or decreased economic exposure to the Shares and/or other securities of the Company.

Item 7.	MATERIALS TO BE FILED AS EXHIBITS.
	99.1 Joint Filing Agreement dated August 11, 2023 among the Reporting Persons (filed herewith).

	99.2 Form of Investor Rights Agreement (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023).

	99.3 Form of PIPE Subscription Agreement (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023).

	99.4 Form of PIPE Subscription Agreement (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023).

	99.5 RTW Side Letter, dated as of February 9, 2023, by and among Compute Health Acquisition Corp., Allurion Technologies Holdings, Inc., Allurion Technologies, Inc., Compute Health LLC, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023).

CUSIP No. G02008102

13D

Page 12 of 13 Pages

	99.6 Amended and Restated RTW PIPE Side Letter Agreement, dated as of May 2, 2023, by and among Compute Health Acquisition Corp., Allurion Technologies Holdings, Inc., Compute Health LLC, Allurion Technologies, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on May 2, 2023).

	99.7 Revenue Interest Financing Agreement, dated as of February 9, 2023, by and among Allurion Technologies, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on February 10, 2023).

	99.8 Convertible Note Purchase Agreement, dated as of February 15, 2023, by and among Allurion Technologies, Inc., Hunter Ventures Limited, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited (filed herewith).

	99.9 Backstop Agreement, dated as of May 2, 2023, by and among Hunter Ventures Limited, Allurion Technologies Holdings, Inc., Allurion Technologies, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Venture Fund Limited and Fortress Credit Corp. (incorporated by reference to the Form 425 filed by the Company with the Securities and Exchange Commission on May 2, 2023).

CUSIP No. G02008102

13D

Page 13 of 13 Pages

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 11, 2023

	RTW INVESTMENTS, LP


	By:	/s/ Roderick Wong
	Name:	Roderick Wong, M.D.
	Title:	Managing Partner


	/s/ Roderick Wong
	RODERICK WONG, M.D.

EX-99 2 p23-2162exhibit99.htm JOINT FILING AGREEMENT

Exhibit 99.1

JOINT FILING AGREEMENT
PURSUANT TO RULE 13(d)-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: August 11, 2023

	RTW INVESTMENTS, LP


	By:	/s/ Roderick Wong
	Name:	Roderick Wong, M.D.
	Title:	Managing Partner


	/s/ Roderick Wong
	RODERICK WONG, M.D.

EX-99 3 p23-2162exhibit99_8.htm EXHIBIT 99.8

Exhibit 99.8

CONVERTIBLE NOTE PURCHASE AGREEMENT

This CONVERTIBLE NOTE PURCHASE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), is made as of February 15, 2023, by and among Allurion Technologies, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A attached to this Agreement (the “Purchasers”).

WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, Convertible Unsecured Promissory Notes in substantially the form attached hereto as Exhibit B (each, as amended, restated, supplemented or otherwise modified from time to time, a “Note” and collectively, the “Notes” and, the equity securities issuable on the conversion of such Notes in accordance with the terms thereof, the “Conversion Shares”), in an aggregate principal amount of up to $20,000,000; and

NOW THEREFORE, in consideration of the foregoing and the representations, warranties and conditions set forth below, the parties hereby agree as follows:

Purchase and Sale of the Notes.

1.1 Sale and Issuance of the Notes. Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at a Closing and the Company agrees to sell and issue to each Purchaser at a Closing a Note in the principal amount set forth opposite such Purchaser’s name on Exhibit A.

1.2

Closing: Delivery.

(a) The initial purchase and sale of the Notes shall take place remotely via the exchange of documents and signatures, on a date mutually agreed by the Company and the Purchasers purchasing Notes at such time (which time and place are designated as the “Initial Closing”). In the event there is more than one closing, the term “Closing” shall apply to each such closing unless otherwise specified and the term “Closings” shall refer collectively to all closings.

(b) At each Closing, the Company shall deliver to each Purchaser party to such Closing a duly executed Note in substantially the form attached hereto as Exhibit B, representing the Note being purchased by such Purchaser at such Closing against payment of the purchase price therefor, as set forth opposite such Purchaser’s name on Exhibit A as amended from time to time in connection with any subsequent Closing (the “Purchase Price”). The Purchase Price shall be paid by wire transfer of immediately available funds to a bank account designated by the Company.

1.3 Sale of Additional Notes. After the Initial Closing, the Company shall sell, on the same terms and conditions as those contained in this Agreement, additional Notes (the “Additional Notes”) at one or more closings to one or more additional purchasers (the “Additional Purchasers”); provided, that

(a) such subsequent sale is consummated on or prior to April 30, 2023, (b) the aggregate principal amount of all Notes issued at all Closings shall not exceed $20,000,000, and (c) each Additional Purchaser (if not currently a party hereto) shall become a party to this Agreement, by executing and delivering a counterpart signature page to this Agreement. Exhibit A to this Agreement shall be updated to reflect the number of Additional Notes purchased at each such Closing and the parties purchasing such Additional Notes.

1.4 Use of Proceeds. The Company will use the proceeds from the sale of the Notes for working capital and other general corporate purposes.

1.5 Defined Terms Used in this Agreement. In addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or referenced below.

(a) “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person or any venture capital, growth equity fund or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisor of, or shares the same management company or investment advisor with, such Person.

(b) “Board of Directors” means the Company’s Board of Directors.

(c) “Certificate of Incorporation” means the Company’s certificate of incorporation, as may be amended or restated from time to time.

(d) “Code” means the Internal Revenue Code of 1986, as amended.

(e) “Direct Listing” means the effectiveness of a registration statement filed under the Securities Act that registers shares of existing capital stock of the Company for resale not pursuant to an underwritten offering.

(f) “Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, condition (financial or otherwise), property or results of operations of the Company.

(g) “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

(h) “Purchaser” means each of the Purchasers who is initially a party to this Agreement and any Additional Purchaser who becomes a party to this Agreement at a subsequent Closing under Subsection 1.3 or has become a Purchaser as a result of an assignment in accordance with Section 7.2.

(i) “SEC” means the Securities and Exchange Commission.

(j) “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

(k) “Stockholder Agreements” means (i) the Fourth Amended and Restated Investors’ Rights Agreement among the Company and certain stockholders of the Company, dated as of July 23, 2021, to be superseded by the Investor Rights and Lock-Up Agreement to be entered into between the Company and certain stockholders of the Company listed as parties thereto (the “Investors Rights Agreement”) (ii) the Amended and Restated Right of First Refusal and Co-Sale Agreement among the Company and certain stockholders of the Company, dated as of July 23, 2021 and (iii) the Amended and Restated Voting Agreement among the Company and certain stockholders of the Company, dated as of July 23, 2021, in each case, as amended or restated from time to time.

(l) “Transaction Agreements” means this Agreement and the Notes.

2. Representations and Warranties of the Company. The Company hereby represents and warrants to each Purchaser that the following representations are true and complete as of the date of this Agreement and the Initial Closing.

2.1 Organization, Good Standing, Corporate Power and Qualification. The Company was duly incorporated and is validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as presently conducted and as currently proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect.

2.2

Capitalization.

(a)

The authorized capital of the Company as of the date of this Agreement consists of:

(i) 35,000,000 shares of Common Stock, 7,654,943 shares of which are issued and outstanding immediately prior to the Initial Closing.

(ii) 21,029,888 shares of Preferred Stock, (a) 2,276,786 of which have been designated Series A Preferred Stock, all of which are issued and outstanding immediately prior to the Initial Closing, (b) 1,513,028 of which have been designated Series A-1 Preferred Stock, 1,485,544 of which are issued and outstanding immediately prior to the Initial Closing, (c) 2,298,929 of which have been designated Series B Preferred Stock, 2,236,793 of which are issued and outstanding immediately prior to the Initial Closing, (d) 8,113,616 of which have been designated Series C Preferred Stock, 7,927,446 of which are issued and outstanding immediately prior to the Initial Closing, (e) 1,684,565 of which have been designated Series D-1 Preferred Stock, 842,283 of which are issued and outstanding immediately prior to the Initial Closing, (f) 3,644,616 of which have been designated Series D-2 Preferred Stock, all of which are issued and outstanding immediately prior to the Initial Closing, and (g) 1,498,348 of which have been designated Series D-3 Preferred Stock, all of which are issued and outstanding immediately prior to the Initial Closing.

(b) The Company has an aggregate of 4,396,765 outstanding options to purchase shares of Common Stock and 1,446,938 shares of Common Stock subject to restricted stock unit awards pursuant to its equity incentive plans, and an additional 356,404 shares of Common Stock reserved for issuance thereunder.

2.3 Subsidiaries. Other than the direct and indirect subsidiaries of the Company (each, a “Subsidiary”), the Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or similar arrangement. Each Subsidiary is duly organized, validly existing and in good standing (or applicable equivalent) under the laws of its jurisdiction of incorporation or formation and has all power and authority required to carry on its business as presently conducted and as proposed to be conducted. Each Subsidiary is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to do so would have a Material Adverse Effect.

2.4 Authorization. All corporate action required to be taken by the Board of Directors and stockholders in order to authorize the Company to enter into this Agreement and to issue the Notes at each Closing has been taken or will be taken prior to such Closing. All action on the part of the officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed as of any Closing, and the issuance and delivery of the Notes has been taken or will be taken prior to such Closing. The Transaction Agreements have been duly executed and delivered by the Company and shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, or (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

2.5

Valid Issuance of Notes.

(a) The Notes, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser.

(b) Assuming the accuracy of the representations of the Purchasers in Section 3 of this Agreement, the Notes will be issued in compliance with all applicable federal and state securities laws. The Conversion Shares issuable upon conversion of the Notes, upon issuance in accordance with, but subject to the conditions, of the Notes and the Certificate of Incorporation in effect at such time of issuance, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Certificate of Incorporation, the Transaction Agreements and the Stockholder Agreements, applicable federal and state securities laws and liens or encumbrances created by or imposed by

a Purchaser. Based in part upon the representations of the Purchasers in Section 3 of this Agreement, the Conversion Shares issuable upon conversion of the Notes will be issued in compliance with all applicable federal and state securities laws.

2.6 Governmental Consents and Filings. Assuming the accuracy of the representations made by the Purchasers in Section 3 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with the execution, delivery and performance of the Transaction Agreements by the Company or the consummation of the transactions contemplated by this Agreement or any other Transaction Agreement.

2.7 Litigation. There is no claim, action, suit, proceeding, arbitration, complaint, charge or investigation pending or, to the Company’s knowledge, currently threatened (a) except for immaterial claims, against the Company or, to the Company’s knowledge, any officer or director of the Company, in each case in their capacity as such, (b) as of the date of this Agreement, that questions the validity or enforceability of (or the execution, delivery or performance by the Company of) the Transaction Agreements or the right of the Company to enter into them, or to consummate the transactions contemplated by the Transaction Agreements, or (c) that would have a Material Adverse Effect.

2.8 Permits. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business as now being conducted by it, the lack of which would have a Material Adverse Effect, and the Company is not in default in any material respect under any of such franchises, permits, licenses or other authority.

2.9 Intellectual Property. To the Company’s knowledge (but without having conducted any special investigation or search), the Company owns or possesses or can acquire on commercially reasonable terms sufficient legal rights to all (a) patents, patent applications and inventions; (b) trademarks, service marks, trade names, trade dress, logos, domain names or corporate names and registrations and applications for registration thereof, together with all of the goodwill associated therewith; (c) copyrights (registered or unregistered) and copyrightable works and registrations and applications for registrations thereof; (d) trade secrets and other confidential information; and (e) information and proprietary rights and processes, in each case, as are necessary for its business as now conducted.

3. Representations and Warranties of the Purchasers. Each Purchaser hereby represents and warrants to the Company, severally and not jointly, that:

3.1 Authorization. The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser, enforceable in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

3.2 Purchase Entirely for Own Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Notes to be acquired by the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Notes.

3.3 Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Notes with the Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon.

3.4 Restricted Securities. The Purchaser understands that the Notes and the Conversion Shares have not been registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Notes and the Conversion Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Notes and the Conversion Shares indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Notes or the Conversion Shares except as set forth in Section 6.3 of this Agreement. The Purchaser further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Notes or the Conversion Shares, and on requirements relating to the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy.

3.5 No Public Market. The Purchaser understands that no public market now exists for the Notes or the Conversion Shares, and that the Company has made no assurances that a public market will ever exist for the Notes or the Conversion Shares.

3.6 Legends. The Purchaser understands that the Notes and the Conversion Shares may be notated with one or all of the following legends:

(a) THE SECURITIES REPRESENTED HEREBY (AND ANY SECURITIES ISSUED UPON CONVERSION OR EXERCISE HEREOF, IF APPLICABLE) HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SECURITIES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

(b) Any legend set forth in, or required by, the other Transaction Agreements.

(c) Any legend required by the securities laws of any state to the extent such laws are applicable to the Notes or the Conversion Shares represented by the certificate, instrument, or book entry so legended.

3.7 Accredited Investor. The Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

3.8 Foreign Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Notes or any use of this Agreement, including (a) the legal requirements within its jurisdiction for the purchase of the Notes, (b) any foreign exchange restrictions applicable to such purchase, (c) any governmental or other consents that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Notes. The Purchaser’s subscription and payment for and continued beneficial ownership of the Notes will not violate any applicable securities or other laws of the Purchaser’s jurisdiction.

3.9 No General Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, shareholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and sale of the Notes.

3.10 Exculpation Among Purchasers. The Purchaser acknowledges that it is not relying upon any Person, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither any Purchaser nor the respective controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Notes.

3.11 Residence. If the Purchaser is an individual, then the Purchaser resides in the state, country or province identified in the address of the Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of the Purchaser in which its principal place of business is identified in the address or addresses of the Purchaser set forth on Exhibit A.

4. Conditions to the Purchasers’ Obligations at Closing. The obligations of each Purchaser to purchase the Notes at the Initial Closing or any other Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived:

4.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct in all material respects (or in all respects to the extent such representation or warranty is already qualified by materiality or a Material Adverse Effect standard) as of the Initial Closing.

4.2 Performance. The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before the Initial Closing or such other Closing.

4.3 Qualifications. All authorizations, waiting period expirations or terminations, clearances, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Notes pursuant to this Agreement and the other Transaction Agreements shall be obtained and effective as of such Closing.

4.4 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated at such Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser purchasing a Note at such Closing, and each such Purchaser (or its counsel) shall have received all copies of such documents as reasonably requested.

4.5 Preemptive Rights. The Company shall have fully satisfied (including with respect to rights of timely notification) or obtained enforceable waivers in respect of any preemptive or similar rights directly or indirectly affecting any of its securities.

5. Conditions of the Company’s Obligations at Closing. The obligations of the Company to sell the Notes to the Purchasers at the applicable Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived.

5.1 Representations and Warranties. The representations and warranties of each Purchaser contained in Section 3 shall be true and correct in all respects as of such Closing.

5.2 Performance. The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them on or before such Closing.

5.3 Subordination Agreement. Each Purchaser shall have executed and delivered the Subordination Agreement (as defined below) to the Company.

Additional Agreements.

6.1 Subordination. The indebtedness represented by the Notes issued pursuant to the terms of this Agreement is unsecured and the Purchasers acknowledge and agree that the obligation of the Company to make payment on the Notes is expressly subordinated in right of payment to all obligations of the Company to Runway Growth Finance Corp. (the “Senior Lender”), pursuant to the Amended and Restated Loan and Security Agreement and the Senior

Lender, dated December 30, 2021, as the same may be amended or restated from time to time, and is subject to that certain Subordination Agreement, dated February 15, 2023, by and among the Company, the Senior Lender, and the creditors party thereto, attached hereto as Exhibit C (as amended or restated from time to time, the “Subordination Agreement”).

6.2 Cooperation. Prior to any issuance of Conversion Shares upon conversion of the Notes, the parties agree to fully cooperate to (a) take, or cause to be taken, all further actions, (b) deliver to the other parties such further information and documents, (c) execute and deliver to the other parties such further instruments, including any amendments to the Certificate of Incorporation, in each case as any other party may reasonably request as is necessary in order to amend the authorized shares of capital stock to create the Conversion Shares and to authorize the Board of Directors to authorize and issue such Conversion Shares in accordance with the Notes or to effect a reorganization of the share capital of the Company, as required and (d) if the Conversion Shares are issued pursuant to Sections 5.2 of the Notes, execute and deliver joinders to the customary stockholder agreements executed by investors in the latest financing round (including, without limitation, the Stockholder Agreements to the extent the applicable Purchaser receiving Conversion Shares is not already party to such agreement(s).

6.3 Registration Rights. In connection with a deSPAC Transaction, the Company will provide registration rights to the Purchasers that are the same as those granted to the investors in the concurrent private placement. In connection with an underwritten initial public offering of shares of common stock of the Company under the Securities Act or a Direct Listing, the Company will provide registration rights to the Purchasers on the same terms as those provided to holders of shares of the Company’s preferred stock as set forth in the Investors Rights Agreement.

6.4 Confidentiality. Each Purchaser hereby agrees to hold in confidence and trust and not to misuse or disclose any confidential information provided pursuant to this Agreement or learned by such Purchaser in connection with the Purchaser’s rights under the Agreement without the prior written consent of the Company except that such Purchaser may disclose such confidential information (i) to any partner, limited partner, member, subsidiary, parent or affiliate of such Purchaser for the purpose of evaluating or monitoring its investment in the Company as long as such partner, limited partner, member, subsidiary, parent or affiliate is advised of the confidentiality provisions of this Section 6.5 and directs such person to maintain the confidentiality of such information; (ii) as required by any court or other governmental body, provided that such Purchaser provides the Company with prompt notice of such court order or requirement to the Company to enable the Company to seek a protective order or otherwise to prevent or restrict such disclosure; (iii) to legal counsel of such Purchaser; (iv) in connection with the enforcement of this Agreement or rights under this Agreement; or (v) to comply with applicable law. The provisions of this Section 6.4 shall be in addition to, and not in substitution for, the provisions of any separate nondisclosure agreement executed by the parties hereto with respect to the transactions contemplated hereby.

6.5 Public Announcements. Notwithstanding any provision to the contrary contained in this Agreement, and subject to the following provisions of this Section 6.5, no party will make any announcements, disclosures, or governmental or regulatory filings as to the subject matter of or parties to this Agreement, except in a form and manner, and at a time, previously

approved in writing by the other party (such approval not to be unreasonably or arbitrarily withheld or delayed). If a party is required to make any such announcement, disclosure, or governmental or regulatory filing as to the subject matter of or parties to this Agreement, that party shall first give notice of the requirement to the other party, consult with the other party, and agree with the other party as to the form and content of the announcement, disclosure or filing (but only to the extent that it identifies and/or discloses information about the other party), in each case to the extent legally permissible.

Miscellaneous.

7.1 Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers contained in or made pursuant to this Agreement or any other Transaction Agreement shall survive the execution and delivery of this Agreement and each other Transaction Agreement and the Closing for a period equal to the longer of (i) one year from the date of this Agreement or (ii) termination of the Notes, whether by payment in full in cash or conversion as provided for herein and in the Notes, and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers or the Company.

7.2 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties; provided, however, that the Company may not assign, convey or transfer its obligations under this Agreement without the written consent of the Requisite Majority; provided that no such consent shall be required for the Company to effect any pre-deSPAC Reorganization or any Reorganization Event that is not a Sale Event (each as defined in the Notes). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any interests, rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

7.3 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law.

7.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

7.5 Headings, Titles and Subtitles. The headings, titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

7.6 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of

actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or Exhibit A, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Subsection 7.6. If notice is given to the Company, a copy shall also be sent to Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210, Attn: Danielle Lauzon and Paul R. Rosie, and if notice is given to the Purchasers, a copy shall also be given to any counsel for a Purchaser as set forth on the signature page or Exhibit A.

7.7 No Finder’s Fees. Each party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. Each Purchaser agrees to indemnify and to hold harmless the Company and each other Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which each Purchaser or any of its officers, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. This Section 7.7 shall survive termination of this Agreement, including by repayment and/or conversion.

7.8 Attorneys’ Fees. If any action at law or in equity (including, arbitration) is necessary to enforce or interpret the terms of any of the Transaction Agreements, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. This Section 7.8 shall survive termination of this Agreement, including by repayment and/or conversion.

7.9 Amendments and Waivers. Except as set forth in Subsection 1.3 of this Agreement, any term of this Agreement may be amended, terminated or waived only with the written consent of the Company and the holders of a majority of the outstanding principal amount of all Notes issued under this Agreement (the “Requisite Majority”). Any amendment or waiver effected in accordance with this Subsection 7.9 shall be binding upon the Purchasers and each transferee of the Notes (or the Conversion Shares), each future holder of all such securities, and the Company.

7.10 Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

7.11 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or

an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

7.12 Entire Agreement. This Agreement (including the Exhibits hereto) and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.

7.13 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware (and any appellate courts thereof) for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Delaware (and any appellate courts thereof), and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

[Remainder of Page Intentionally Left Blank]